Sort by:
Need a comprehensive medical report on "A"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45
Phase 1
Not yet recruiting
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- Drug: ENTR-601-45 - matching placebo
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Entrada Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT07038824
- Locations
- 🇧🇪
University Hospital Gent, Gent, Belgium
🇧🇪UZ Leuven, Leuven, Belgium
🇮🇹IRCCS Ospedale San Raffaele, Milan, Italy
A Multicenter, Prospective, Randomized, Controlled Clinical Study on the Effect of Hysteroscopic Uterine Septum Resection on the Natural Pregnancy Outcomes in Patients With Non-recurrent Spontaneous Abortion
Not Applicable
Recruiting
- Conditions
- Infertility and Miscarriage
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Target Recruit Count
- 418
- Registration Number
- NCT07039097
- Locations
- 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
Phase 2
Recruiting
- Conditions
- Schizophrenia
- Interventions
- Drug: ML-007C-MA QDDrug: ML-007C-MA BIDDrug: Placebo
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- MapLight Therapeutics
- Target Recruit Count
- 300
- Registration Number
- NCT07038876
- Locations
- 🇺🇸
Clinical Site, Richardson, Texas, United States
A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 1
Recruiting
- Conditions
- HER 2 Positive Gastric CancerGastroesophageal Junction Adenocarcinoma
- Interventions
- Drug: AUR103 CalciumDrug: Trastuzumab + CAPOX (Capecitabine + Oxaliplatin)
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Aurigene Discovery Technologies Limited
- Target Recruit Count
- 18
- Registration Number
- NCT07040059
- Locations
- 🇮🇳
HCG Cancer Center, Vizag, Andhra Pradesh, India
🇮🇳Shalby Hospital, Ahmedabad, Gujarat, India
🇮🇳The Gujarat Cancer & Research Insititute, Ahmedabad, Gujarat, India
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
Phase 3
Not yet recruiting
- Conditions
- GERD (Gastroesophageal Reflux Disease)
- Interventions
- Drug: Linaprazan glurate 50 mg Twice Daily (BID)Drug: Linaprazan Glurate 50 mg Once Daily (QD)Drug: Lansoprazole 30 mg Once Daily (QD)
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Cinclus Pharma Holding AB
- Target Recruit Count
- 500
- Registration Number
- NCT07037875
- Locations
- 🇺🇸
Del Sol Research Management, LLC, Tucson, Arizona, United States
🇺🇸Gastro Care Institute, Lancaster, California, United States
🇺🇸Rocky Mountain Gastroenterology Associates - Littleton, Littleton, Colorado, United States
Comparison of Two Strategies for Administering the R21-Matrix M Vaccine in a Context of Seasonal Malaria Transmission in Chad
Phase 4
Not yet recruiting
- Conditions
- Malaria InfectionMalaria Vaccines
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Epicentre
- Target Recruit Count
- 70000
- Registration Number
- NCT07038837
- Locations
- 🇹🇩
Medecin sans Frontières, Moissala, Mandoul region, Chad
Efficacy of Ketorolac for Postoperative Pain Management in Hip Arthroscopy: A Prospective Double-Blinded Randomized Controlled Trial
Phase 4
Recruiting
- Conditions
- Femoracetabular ImpingementHip Arthroscopy
- Interventions
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Henry Ford Health System
- Target Recruit Count
- 100
- Registration Number
- NCT07037888
- Locations
- 🇺🇸
Henry Ford Health, Detroit, Michigan, United States
STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1
Phase 2
Not yet recruiting
- Conditions
- Lung Squamous Cell CarcinomaAnti-PD1/PDL1 Antibody
- Interventions
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT07038915
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Phase 1
Recruiting
- Conditions
- Solid Tumor CancerLocally AdvancedMetastatic Solid TumorsLung CancersEpithelial Tumor
- Interventions
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Avenzo Therapeutics, Inc.
- Target Recruit Count
- 430
- Registration Number
- NCT07038343
- Locations
- 🇺🇸
Avenzo Therapeutics Recruiting Site, Fairfax, Virginia, United States
A Computer-based Memory Strategy Training Program for Older Adults
Not Applicable
Recruiting
- Conditions
- Healthy Older AdultsMemory ComplaintsMild Cognitive Impairment (MCI)
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- The Hong Kong Polytechnic University
- Target Recruit Count
- 60
- Registration Number
- NCT07039708
- Locations
- 🇭🇰
The Hong Kong Polytechnic University, Hong Kong, Hong Kong